These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16601476)

  • 41. Second-trimester sonographic soft markers: what can we learn from the experience of first-trimester nuchal translucency screening?
    Lau TK; Evans MI
    Ultrasound Obstet Gynecol; 2008 Aug; 32(2):123-5. PubMed ID: 18663770
    [No Abstract]   [Full Text] [Related]  

  • 42. Nuchal translucency screening in monochorionic twin pregnancies.
    Zoppi MA
    Ultrasound Obstet Gynecol; 2009 Nov; 34(5):491-3. PubMed ID: 19852038
    [No Abstract]   [Full Text] [Related]  

  • 43. Factors influencing visualization of the intracranial translucency during first-trimester screening for aneuploidy.
    Beamon CJ; Stuebe AM; Wolfe HM
    Am J Perinatol; 2012 Aug; 29(7):503-8. PubMed ID: 22495902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of first and second trimester aneuploidy risk assessment.
    Reddy UM; Wapner RJ
    Clin Obstet Gynecol; 2007 Jun; 50(2):442-53. PubMed ID: 17513930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome.
    Lam YH; Lee CP; Sin SY; Tang R; Wong HS; Wong SF; Fong DY; Tang MH; Woo HH
    Prenat Diagn; 2002 Aug; 22(8):730-5. PubMed ID: 12210586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
    Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
    Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First-trimester contingent screening for Down syndrome can reduce the number of nuchal translucency measurements required.
    Vadiveloo T; Crossley JA; Aitken DA
    Prenat Diagn; 2009 Jan; 29(1):79-82. PubMed ID: 19097036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies.
    Spencer K
    Prenat Diagn; 2001 Jun; 21(6):445-7. PubMed ID: 11438946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
    Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Screening for Down's syndrome by fetal nuchal translucency measurement in a high-risk population.
    Pajkrt E; Mol BW; van Lith JM; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):156-62. PubMed ID: 9793186
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome.
    Kadir RA; Economides DL
    Ultrasound Obstet Gynecol; 1997 Apr; 9(4):244-7. PubMed ID: 9168574
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of intracranial translucency and 3D sonography in the first trimester diagnosis of neural tube defects: case report and review of literature.
    Peker N; Yeniel AO; Ergenoglu M; Hurşitoğlu S; Akercan F; Karadadaş N
    Ginekol Pol; 2013 Jan; 84(1):65-7. PubMed ID: 23488313
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Additional first-trimester ultrasound markers.
    Sonek J; Nicolaides K
    Clin Lab Med; 2010 Sep; 30(3):573-92. PubMed ID: 20638573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Technical aspects of nuchal translucency measurement.
    Abuhamad A
    Semin Perinatol; 2005 Dec; 29(6):376-9. PubMed ID: 16533650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Screening for Down syndrome.
    Spencer K
    Scand J Clin Lab Invest Suppl; 2014; 244():41-7. PubMed ID: 25083892
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening.
    Hackshaw A; Wald N
    Prenat Diagn; 2002 Nov; 22(11):1051-3. PubMed ID: 12424775
    [No Abstract]   [Full Text] [Related]  

  • 59. Jugular lymphatic sacs in the first trimester of pregnancy: the prevalence and the potential value in screening for chromosomal abnormalities.
    van Heesch PN; Struijk PC; Brandenburg H; Steegers EA; Wildschut HI
    J Perinat Med; 2008; 36(6):518-22. PubMed ID: 18681837
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Second and first trimester estimation of risk for Down syndrome: implementation and performance in the SAFER study.
    MacRae AR; Chodirker BN; Davies GA; Palomaki GE; Knight GJ; Minett J; Kavsak PA; Toi A; Chitayat D; Van Caeseele PG
    Prenat Diagn; 2010 May; 30(5):459-66. PubMed ID: 20440734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.